Fulcrum Therapeutics, Inc.
FULC
$6.92
-$0.51-6.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | -37.24M | 14.30M | 12.99M | 13.40M | -47.02M |
| Gross Profit | 37.24M | -14.30M | -12.99M | -13.40M | 47.02M |
| SG&A Expenses | 7.28M | 7.56M | 6.83M | 7.00M | 7.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.69M | 21.86M | 19.82M | 20.40M | 19.43M |
| Operating Income | -22.69M | -21.86M | -19.82M | -20.40M | -19.43M |
| Income Before Tax | -20.33M | -19.60M | -17.30M | -17.66M | -16.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.33M | -19.60M | -17.30M | -17.66M | -16.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.33M | -19.60M | -17.30M | -17.66M | -16.57M |
| EBIT | -22.69M | -21.86M | -19.82M | -20.40M | -19.43M |
| EBITDA | -22.35M | -21.51M | -19.47M | -20.05M | -19.06M |
| EPS Basic | -0.31 | -0.31 | -0.28 | -0.28 | -0.31 |
| Normalized Basic EPS | -0.19 | -0.20 | -0.17 | -0.18 | -0.19 |
| EPS Diluted | -0.31 | -0.31 | -0.28 | -0.28 | -0.31 |
| Normalized Diluted EPS | -0.19 | -0.20 | -0.17 | -0.18 | -0.19 |
| Average Basic Shares Outstanding | 65.78M | 62.60M | 62.54M | 62.48M | 53.95M |
| Average Diluted Shares Outstanding | 65.78M | 62.60M | 62.54M | 62.48M | 53.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |